Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions
Ella Day | May 20, 2025 | News story | Research and Development | Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology
Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off biotech seeks to develop therapeutics for patients living with fibrotic, neoplastic and neovascularised conditions. Through this unique paradigm, researchers hope to find new ways to address these interlinked issues.
Massalia builds on decades of research conducted at Aix-Marseille’s C2VN, a leading cardiovascular research unit in France and where the biotech will be based. This has accumulated in the identification of a new therapeutic platform, Soluble Angiogenic Neoplastic and Fibrotic (SANF) factor which the new biotech intends to advance.
“Given SANF’s wide ranging potential in oncology and fibrosis, we are confident that this therapeutic platform can redefine treatment paradigms in these challenging diseases,” commented Zaki Sellam, executive chairman at Massalia and CEO and co-founder of Landmark BioVentures.
Researchers at Massalia have an array of academic and strategic support in France, namely from Aix-Marseille University, Marseille University Hospitals and SATT Sud-Est (a regional economic development agency), in addition to C2VN.
“We are excited to support this talented team as they work to bring their sole-in-class platform, targeting the SANF factor, to market, supporting patients in need,” added Françoise Dignat-George, director at C2VN.
Massalia Therapeutics is progressing towards clinical candidate nomination and plans to enter studies in six to 12 months’ time.
Ella Day
20/5/25
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe
